Autochecked users, Comment administrators, Editors, Interface administrators, Reviewers, Suppressors, Administrators, Widget editors
1,874
edits
Changes
no edit summary
==Cancer Category/Type==
==Cancer Category/Type==
'''Clonal Hematopoiesis of Indeterminate Potential (CHIP; premalignant)'''
'''Myelodysplastic Syndrome (MDS)'''
Recurrent TET2 mutation was first reported in myelodysplastic syndrome (MDS) patients with chromosome 4q24 abnormalities. In this cohort ''TET2'' mutations have been observed in 19-26% of patients and are among the most common genetic lesions (Delhommeau et al., 2009; Langemeijer et al., 2009). Cell lineage evidence supports the notion that ''TET2'' mutations occur very early during disease evolution (Itzykson et al., 2013a; Langemeijer et al., 2009). ''TET2'' mutations are overrepresented in samples with normal cytogenetics (Bejar et al., 2011). Mutations in ''EZH2'' occur in as many as 35% of ''TET2''-mutated MDS (Muto et al., 2013). There is no impact of ''TET2'' mutations on overall survival, but their presence may predict response to hypomethylating agents (Bejar et al., 2011; Itzykson et al., 2011).
Recurrent TET2 mutation was first reported in myelodysplastic syndrome (MDS) patients with chromosome 4q24 abnormalities. In this cohort ''TET2'' mutations have been observed in 19-26% of patients and are among the most common genetic lesions (Delhommeau et al., 2009; Langemeijer et al., 2009). Cell lineage evidence supports the notion that ''TET2'' mutations occur very early during disease evolution (Itzykson et al., 2013a; Langemeijer et al., 2009). ''TET2'' mutations are overrepresented in samples with normal cytogenetics (Bejar et al., 2011). Mutations in ''EZH2'' occur in as many as 35% of ''TET2''-mutated MDS (Muto et al., 2013). There is no impact of ''TET2'' mutations on overall survival, but their presence may predict response to hypomethylating agents (Bejar et al., 2011; Itzykson et al., 2011).
'''[[HAEM5:Chronic myelomonocytic leukaemia]]'''
Approximately 60% of chronic myelomonocytic leukemia (CMML) is ''TET2'' mutated (Itzykson et al., 2013b). In CMML ''TET2'' mutations are associated with low-risk cytogenetics and a lower platelet count, typically co-occur with mutations in the splicing gene ''SRSF2'', and are mutually exclusive with ''IDH1'' and ''IDH2'' mutations. ''TET2'' mutation has not previously been found to confer an overall survival advantage (Itzykson et al., 2013b), although a more recent study suggests there is enhanced overall survival in ''TET2''-mutated CMML in the absence of ''ASXL1'' mutations (Patnaik et al., 2016).
Approximately 60% of chronic myelomonocytic leukemia (CMML) is ''TET2'' mutated (Itzykson et al., 2013b). In CMML ''TET2'' mutations are associated with low-risk cytogenetics and a lower platelet count, typically co-occur with mutations in the splicing gene ''SRSF2'', and are mutually exclusive with ''IDH1'' and ''IDH2'' mutations. ''TET2'' mutation has not previously been found to confer an overall survival advantage (Itzykson et al., 2013b), although a more recent study suggests there is enhanced overall survival in ''TET2''-mutated CMML in the absence of ''ASXL1'' mutations (Patnaik et al., 2016).
'''[[HAEM4:Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms]]'''
In acute myeloid leukemia (AML) ''TET2'' mutations occur in around 28% of patients, of which half have mutations in both alleles (Weissmann et al., 2012). They occur more frequently in patients with normal karyotype and are associated with higher white blood cell counts, lower platelet counts, and a higher age at diagnosis. ''TET2'' mutations predict lower event-free survival, particularly in patients younger than 65 years old and those in the European LeukemiaNet (ELN) favourable-risk subgroup. Overall survival does not seem to be impacted except for in patients with ''TET2'' mutation and intermediate-risk AML, where overall survival is reduced (Patel et al., 2012; Weissmann et al., 2012). There is a strong correlation with ''JAK2'' mutations occurring in patients with ''TET2''-mutated secondary AML after myeloproliferative neoplasm, and there is a highly inverse association between ''TET2'' mutations and mutations in ''IDH1'' and ''IDH2'' (Weissmann et al., 2012). This inverse association is also observed for ''TET2'' and ''WT1'' mutations, and TET2 and WT1 physically interact, suggesting overlapping pathways for these genes in AML (Wang et al., 2015). ''TET2'' mutations increase the response of low blast count AML patients to the hypomethylating agent azacitidine (Itzykson et al., 2011).
In acute myeloid leukemia (AML) ''TET2'' mutations occur in around 28% of patients, of which half have mutations in both alleles (Weissmann et al., 2012). They occur more frequently in patients with normal karyotype and are associated with higher white blood cell counts, lower platelet counts, and a higher age at diagnosis. ''TET2'' mutations predict lower event-free survival, particularly in patients younger than 65 years old and those in the European LeukemiaNet (ELN) favourable-risk subgroup. Overall survival does not seem to be impacted except for in patients with ''TET2'' mutation and intermediate-risk AML, where overall survival is reduced (Patel et al., 2012; Weissmann et al., 2012). There is a strong correlation with ''JAK2'' mutations occurring in patients with ''TET2''-mutated secondary AML after myeloproliferative neoplasm, and there is a highly inverse association between ''TET2'' mutations and mutations in ''IDH1'' and ''IDH2'' (Weissmann et al., 2012). This inverse association is also observed for ''TET2'' and ''WT1'' mutations, and TET2 and WT1 physically interact, suggesting overlapping pathways for these genes in AML (Wang et al., 2015). ''TET2'' mutations increase the response of low blast count AML patients to the hypomethylating agent azacitidine (Itzykson et al., 2011).
'''Angioimmunoblastic T-cell Lymphoma (AITL) and Other Nodal Lymphoma of T-follicular Helper (TFH) Cell Origin'''
''TET2'' mutations are observed frequently in angioimmunoblastic lymphoma (AITL), with mutation rates of 30-80% depending on study (Odejide et al., 2014; Quivoron et al., 2011). Many ''TET2''-mutated AITLs harbour multiple ''TET2'' mutations. There is a strong positive correlation with ''DNMT3A'' mutation, a trend towards older age at diagnosis, and an increased association with elevated lactate dehydrogenase (LDH) (Odejide et al., 2014). Around 20% of ''TET2''-mutated AITL also carry an ''IDH2'' mutation, which is in stark contrast with the strong negative correlation between these two genes in other haematological malignancies (Odejide et al., 2014). No difference in overall survival is evident for ''TET2''-mutated AITL compared to wild-type.
''TET2'' mutations are observed frequently in angioimmunoblastic lymphoma (AITL), with mutation rates of 30-80% depending on study (Odejide et al., 2014; Quivoron et al., 2011). Many ''TET2''-mutated AITLs harbour multiple ''TET2'' mutations. There is a strong positive correlation with ''DNMT3A'' mutation, a trend towards older age at diagnosis, and an increased association with elevated lactate dehydrogenase (LDH) (Odejide et al., 2014). Around 20% of ''TET2''-mutated AITL also carry an ''IDH2'' mutation, which is in stark contrast with the strong negative correlation between these two genes in other haematological malignancies (Odejide et al., 2014). No difference in overall survival is evident for ''TET2''-mutated AITL compared to wild-type.
''TET2'' mutations are associated with a T-follicular like cellular phenotype and may be associated with non-AITL TFH subtypes, as defined by the World Health Organisation (Swerdlow et al., 2017).
''TET2'' mutations are associated with a T-follicular like cellular phenotype and may be associated with non-AITL TFH subtypes, as defined by the World Health Organisation (Swerdlow et al., 2017).
'''Peripheral T-cell Lymphoma (PTCL)'''
Peripheral T-cell lymphoma (PTCL) is ''TET2''-mutated at a frequency of ~20-40% (Lemonnier et al., 2012; Quivoron et al., 2011). ''TET2'' mutations in this disease correlate with T follicular helper cell features or features similar to AITL in addition to advanced-stage disease and shorter progression-free survival (Lemonnier et al., 2012).
Peripheral T-cell lymphoma (PTCL) is ''TET2''-mutated at a frequency of ~20-40% (Lemonnier et al., 2012; Quivoron et al., 2011). ''TET2'' mutations in this disease correlate with T follicular helper cell features or features similar to AITL in addition to advanced-stage disease and shorter progression-free survival (Lemonnier et al., 2012).
'''[[Diffuse large B-cell lymphoma]]'''
''TET2'' mutations are observed in diffuse large B-cell lymphoma (DLBCL) at a rate of 6-15% (Asmar et al., 2011; Quivoron et al., 2011). They do not appear to confer prognostic value in DLBCL, and are not observed in other B-cell neoplasms.
''TET2'' mutations are observed in diffuse large B-cell lymphoma (DLBCL) at a rate of 6-15% (Asmar et al., 2011; Quivoron et al., 2011). They do not appear to confer prognostic value in DLBCL, and are not observed in other B-cell neoplasms.
'''Glioma'''
''IDH1/2'' mutations are observed frequently in grades II and III gliomas and secondary glioblastomas (Yan et al., 2009), but despite the overlapping pathways between the ''IDH1/2'' and ''TET2'' genes mutations in the latter are rarely observed in glioma and do not appear to have pathogenic effect (Kraus et al., 2015). However, ''TET2'' promoter methylation has been observed in ''IDH1/2'' wild-type but not mutant glioma suggesting that methylation of the ''TET2'' promoter and not coding region mutations are biologically relevant in this disease (Kim et al., 2011).
''IDH1/2'' mutations are observed frequently in grades II and III gliomas and secondary glioblastomas (Yan et al., 2009), but despite the overlapping pathways between the ''IDH1/2'' and ''TET2'' genes mutations in the latter are rarely observed in glioma and do not appear to have pathogenic effect (Kraus et al., 2015). However, ''TET2'' promoter methylation has been observed in ''IDH1/2'' wild-type but not mutant glioma suggesting that methylation of the ''TET2'' promoter and not coding region mutations are biologically relevant in this disease (Kim et al., 2011).
'''Prostate Cancer'''
In prostate cancer ''TET2'' is downregulated, possibly through androgen receptor-mediated induction of the miR-29 microRNA family, and loss of ''TET2'' expression is associated with cancer progression (Takayama et al., 2015). Germline ''TET2'' variants may also be a risk factor for prostate cancer (Koutros et al., 2013).
In prostate cancer ''TET2'' is downregulated, possibly through androgen receptor-mediated induction of the miR-29 microRNA family, and loss of ''TET2'' expression is associated with cancer progression (Takayama et al., 2015). Germline ''TET2'' variants may also be a risk factor for prostate cancer (Koutros et al., 2013).
'''Ovarian Cancer'''
Exome sequencing of ovarian clear cell carcinoma revealed frequent (73%) copy number losses affecting ''TET2'' (Kim et al., 2018). DNA demethylation, measured by 5-hmC levels, and ''TET2'' expression appear to hold prognostic value in epithelial ovarian cancer, with higher values significantly associated with improved overall survival (Zhang et al., 2015).
Exome sequencing of ovarian clear cell carcinoma revealed frequent (73%) copy number losses affecting ''TET2'' (Kim et al., 2018). DNA demethylation, measured by 5-hmC levels, and ''TET2'' expression appear to hold prognostic value in epithelial ovarian cancer, with higher values significantly associated with improved overall survival (Zhang et al., 2015).
'''Breast Cancer'''
Reduction of 5hmC and ''TET2'' expression is associated with disease progression in breast cancer and may predict a poorer overall survival (Tsai et al., 2015; Yang et al., 2015). Germline variants in the ''TET2'' promoter and enhancer regions may correlate with increased breast cancer risk (Guo et al., 2015).
Reduction of 5hmC and ''TET2'' expression is associated with disease progression in breast cancer and may predict a poorer overall survival (Tsai et al., 2015; Yang et al., 2015). Germline variants in the ''TET2'' promoter and enhancer regions may correlate with increased breast cancer risk (Guo et al., 2015).
'''Colorectal Cancer'''
Loss of ''TET2'' nuclear localisation has been observed in colorectal cancer cells in association with metastasis (Huang et al., 2016). Colorectal cancer cells exhibit reduced ''TET2'' transcript levels, while patients with high ''TET2'' mRNA levels in cells from histologically unchanged tissue have higher overall survival (Rawłuszko-Wieczorek et al., 2015).
Loss of ''TET2'' nuclear localisation has been observed in colorectal cancer cells in association with metastasis (Huang et al., 2016). Colorectal cancer cells exhibit reduced ''TET2'' transcript levels, while patients with high ''TET2'' mRNA levels in cells from histologically unchanged tissue have higher overall survival (Rawłuszko-Wieczorek et al., 2015).
'''Gastric Cancer'''
5-hmC and ''TET2'' expression levels in gastric cancer are also decreased (Du et al., 2015), and reduced 5-hmC levels may be an independent poor prognostic factor in these patients (Deng et al., 2016; Yang et al., 2013). ''TET2'' may have protective effects against DNA methylation in gastric epithelial cells following Epstein-Barr virus (EBV) infection (Namba-Fukuyo et al., 2016).
5-hmC and ''TET2'' expression levels in gastric cancer are also decreased (Du et al., 2015), and reduced 5-hmC levels may be an independent poor prognostic factor in these patients (Deng et al., 2016; Yang et al., 2013). ''TET2'' may have protective effects against DNA methylation in gastric epithelial cells following Epstein-Barr virus (EBV) infection (Namba-Fukuyo et al., 2016).
'''Endometrial Cancer'''
Increased metastasis and disease stage in endometrial cancer is correlated with decreased ''TET2'' expression levels (Ciesielski et al., 2017). In contrast with breast and prostate cancer, at least one germline ''TET2'' variant (rs7679673) may predict decreased risk for this disease (Setiawan et al., 2014).
Increased metastasis and disease stage in endometrial cancer is correlated with decreased ''TET2'' expression levels (Ciesielski et al., 2017). In contrast with breast and prostate cancer, at least one germline ''TET2'' variant (rs7679673) may predict decreased risk for this disease (Setiawan et al., 2014).
==Common Alteration Types==
==Common Alteration Types==
The most common alterations appearing in the COSMIC database of somatic mutations are missense mutations in the C-terminal catalytic domain (e.g. c.5284A>G p.I1762V, c.5162T>G p.L1721W, c.5618T>C p.I1873T; all NM_001127208.2 ) or nonsense mutations which truncate the catalytic domain (e.g. c.1648C>T p.R550*, c.4393C>T p.R1465*, c.2746C>T p.Q916*; all NM_001127208.2) (source: COSMIC). The catalytic domain lies between residues 1290 and 1905 (NM_001127208.2) based on alignment similarity (source: Pfam).
{| class="wikitable sortable"
{| class="wikitable sortable"
==External Links==
==External Links==
'''[http://atlasgeneticsoncology.org/Genes/TET2ID40597ch4q24.html ''TET2'' by Atlas of Genetics and Cytogenetics in Oncology and Haematology]''' - detailed gene information
'''[https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TET2 ''TET2'' by COSMIC]''' - sequence information, expression, catalogue of mutations
'''[http://atlasgeneticsoncology.org/Genes/P53ID88.html ''TP53'' by Atlas of Genetics and Cytogenetics in Oncology and Haematology]''' - detailed gene information
'''[https://civicdb.org/events/genes/55/summary/variants/157/summary ''TET2'' by CIViC]''' - general knowledge and evidence-based variant specific information
'''[https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TP53 ''TP53'' by COSMIC]''' - sequence information, expression, catalogue of mutations
'''[https://pecan.stjude.cloud/proteinpaint/TET2 ''TET2'' by St. Jude ProteinPaint]''' - mutational landscape and matched expression data
'''[https://civicdb.org/events/genes/45/summary/variants/1300/summary ''TP53'' by CIViC]''' - general knowledge and evidence-based variant specific information
'''[https://pmkb.weill.cornell.edu/genes/23 ''TET2'' by Precision Medicine Knowledgebase (Weill Cornell)]''' - manually vetted interpretations of variants and CNVs
'''[http://p53.iarc.fr/ ''TP53'' by IARC]''' - ''TP53'' database with reference sequences and mutational landscape
'''[http://www.cancer-genetics.org/TET2.htm ''TET2'' by Cancer Index]''' - gene, pathway, publication information matched to cancer type
'''[https://pecan.stjude.cloud/proteinpaint/tp53 ''TP53'' by St. Jude ProteinPaint]''' mutational landscape and matched expression data.
'''[http://oncokb.org/#/gene/TET2 ''TET2'' by OncoKB]''' - mutational landscape, mutation effect, variant classification
'''[https://pmkb.weill.cornell.edu/search?utf8=%E2%9C%93&search=tp53 ''TP53'' by Precision Medicine Knowledgebase (Weill Cornell)]''' - manually vetted interpretations of variants and CNVs
'''[https://www.mycancergenome.org/content/gene/tet2/ ''TET2'' by My Cancer Genome]''' - brief gene overview
'''[http://www.cancerindex.org/geneweb/TP53.htm ''TP53'' by Cancer Index]''' - gene, pathway, publication information matched to cancer type
'''[https://www.uniprot.org/uniprot/Q6N021 ''TET2'' by UniProt]''' - protein and molecular structure and function
'''[http://oncokb.org/#/gene/TP53 ''TP53'' by OncoKB]''' - mutational landscape, mutation effect, variant classification
'''[http://pfam.xfam.org/protein/Q6N021 ''TET2'' by Pfam]''' - gene and protein structure and function information
'''[https://www.mycancergenome.org/content/gene/tp53/ ''TP53'' by My Cancer Genome]''' - brief gene overview
'''[https://www.genecards.org/cgi-bin/carddisp.pl?gene=TET2 ''TET2'' by GeneCards]''' - general gene information and summaries
==References==
*Asmar, F., Christensen, J., Johansen, J.V., Blåbjerg, A., Pedersen, A., Hother, C., Ralfkiaer, U., Helin, K., and Grønbæk, K. (2011). TET2 mutations in Diffuse Large B-Cell Lymphoma: The Role of TET2 in the Regulation of Methylation Patterns at TET2 Target Genes. Blood 118, 1364–1364. PMID:
*Bejar, R., Stevenson, K., Abdel-Wahab, O., Galili, N., Nilsson, B., Garcia-Manero, G., Kantarjian, H., Raza, A., Levine, R.L., Neuberg, D., et al. (2011). Clinical effect of point mutations in myelodysplastic syndromes. N. Engl. J. Med. 364, 2496–2506. PMID: 21714648
*Busque, L., Patel, J.P., Figueroa, M., Vasanthakumar, A., Provost, S., Hamilou, Z., Mollica, L., Li, J., Viale, A., Heguy, A., et al. (2012). Recurrent Somatic TET2 Mutations in Normal Elderly Individuals With Clonal Hematopoiesis. Nat Genet 44, 1179–1181. PMID: 23001125
*Chen, Q., Chen, Y., Bian, C., Fujiki, R., and Yu, X. (2013). TET2 promotes histone O-GlcNAcylation during gene transcription. Nature 493, 561–564. PMID: 23222540
*Ciesielski, P., Jóźwiak, P., Wójcik-Krowiranda, K., Forma, E., Cwonda, Ł., Szczepaniec, S., Bieńkiewicz, A., Bryś, M., and Krześlak, A. (2017). Differential expression of ten-eleven translocation genes in endometrial cancers. Tumour Biol. 39, 1010428317695017. PMID: 28349832
*Cimmino, L., Abdel-Wahab, O., Levine, R.L., and Aifantis, I. (2011). TET family proteins and their role in stem cell differentiation and transformation. Cell Stem Cell 9, 193–204. PMID: 21885017
*Delhommeau, F., Dupont, S., Della Valle, V., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009). Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 360, 2289–2301. PMID: 19474426
*Deng, W., Wang, J., Zhang, J., Cai, J., Bai, Z., and Zhang, Z. (2016). TET2 regulates LncRNA-ANRIL expression and inhibits the growth of human gastric cancer cells. IUBMB Life 68, 355–364. PMID: 27027260
*Deplus, R., Delatte, B., Schwinn, M.K., Defrance, M., Méndez, J., Murphy, N., Dawson, M.A., Volkmar, M., Putmans, P., Calonne, E., et al. (2013). TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS. The EMBO Journal 32, 645–655. PMID: 23353889
*Du, C., Kurabe, N., Matsushima, Y., Suzuki, M., Kahyo, T., Ohnishi, I., Tanioka, F., Tajima, S., Goto, M., Yamada, H., et al. (2015). Robust quantitative assessments of cytosine modifications and changes in the expressions of related enzymes in gastric cancer. Gastric Cancer 18, 516–525. PMID: 25098926
*Figueroa, M.E., Abdel-Wahab, O., Lu, C., Ward, P.S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H.F., et al. (2010). Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18, 553–567. PMID: 21130701
*Guo, X., Long, J., Zeng, C., Michailidou, K., Ghoussaini, M., Bolla, M.K., Wang, Q., Milne, R.L., Shu, X.-O., Cai, Q., et al. (2015). Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 24, 1680–1691. PMID: 26354892
*Huang, Y., Wang, G., Liang, Z., Yang, Y., Cui, L., and Liu, C.-Y. (2016). Loss of nuclear localization of TET2 in colorectal cancer. Clin Epigenetics 8, 9. PMID: 26816554
*Itzykson, R., Kosmider, O., Cluzeau, T., Mansat-De Mas, V., Dreyfus, F., Beyne-Rauzy, O., Quesnel, B., Vey, N., Gelsi-Boyer, V., Raynaud, S., et al. (2011). Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 25, 1147–1152. PMID: 21494260
*Itzykson, R., Kosmider, O., Renneville, A., Morabito, M., Preudhomme, C., Berthon, C., Adès, L., Fenaux, P., Platzbecker, U., Gagey, O., et al. (2013a). Clonal architecture of chronic myelomonocytic leukemias. Blood 121, 2186–2198. PMID: 23319568
*Itzykson, R., Kosmider, O., Renneville, A., Gelsi-Boyer, V., Meggendorfer, M., Morabito, M., Berthon, C., Adès, L., Fenaux, P., Beyne-Rauzy, O., et al. (2013b). Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia. Journal of Clinical Oncology 31, 2428–2436. PMID: 23690417
*Kim, S.I., Lee, J.W., Lee, M., Kim, H.S., Chung, H.H., Kim, J.-W., Park, N.H., Song, Y.-S., and Seo, J.-S. (2018). Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing. Gynecol. Oncol. 148, 375–382. PMID: 29233531
*Kim, Y.-H., Pierscianek, D., Mittelbronn, M., Vital, A., Mariani, L., Hasselblatt, M., and Ohgaki, H. (2011). TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1/2 mutations. J. Clin. Pathol. 64, 850–852. PMID: 21690245
*Ko, M., An, J., Bandukwala, H.S., Chavez, L., Aijö, T., Pastor, W.A., Segal, M.F., Li, H., Koh, K.P., Lähdesmäki, H., et al. (2013). Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX. Nature 497, 122–126. PMID: 23563267
*Koutros, S., Berndt, S.I., Hughes Barry, K., Andreotti, G., Hoppin, J.A., Sandler, D.P., Yeager, M., Burdett, L.A., Yuenger, J., Alavanja, M.C.R., et al. (2013). Genetic Susceptibility Loci, Pesticide Exposure and Prostate Cancer Risk. PLoS One 8. PMID: 23593118
*Kraus, T.F.J., Greiner, A., Steinmaurer, M., Dietinger, V., Guibourt, V., and Kretzschmar, H.A. (2015). Genetic Characterization of Ten-Eleven-Translocation Methylcytosine Dioxygenase Alterations in Human Glioma. J Cancer 6, 832–842. PMID: 26284134
*Kunimoto, H., Fukuchi, Y., Sakurai, M., Sadahira, K., Ikeda, Y., Okamoto, S., and Nakajima, H. (2012). Tet2 disruption leads to enhanced self-renewal and altered differentiation of fetal liver hematopoietic stem cells. Sci Rep 2, 273. PMID: 22355785
*Langemeijer, S.M.C., Kuiper, R.P., Berends, M., Knops, R., Aslanyan, M.G., Massop, M., Stevens-Linders, E., Hoogen, P. van, Kessel, A.G. van, Raymakers, R.A.P., et al. (2009). Acquired mutations in TET2 are common in myelodysplastic syndromes. Nature Genetics 41, 838–842. PMID: 19483684
*Lemonnier, F., Couronné, L., Parrens, M., Jaïs, J.-P., Travert, M., Lamant, L., Tournillac, O., Rousset, T., Fabiani, B., Cairns, R.A., et al. (2012). Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood 120, 1466–1469. PMID: 22760778
*Lorsbach, R.B., Moore, J., Mathew, S., Raimondi, S.C., Mukatira, S.T., and Downing, J.R. (2003). TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia 17, 637–641. PMID: 12646957
*Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, M.E., Vasanthakumar, A., Patel, J., Zhao, X., et al. (2011). Tet2 Loss Leads to Increased Hematopoietic Stem Cell Self-Renewal and Myeloid Transformation. Cancer Cell 20, 11–24. PMID: 21723200
*Muto, T., Sashida, G., Oshima, M., Wendt, G.R., Mochizuki-Kashio, M., Nagata, Y., Sanada, M., Miyagi, S., Saraya, A., Kamio, A., et al. (2013). Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders. Journal of Experimental Medicine 210, 2627–2639. PMID: 24218139
*Namba-Fukuyo, H., Funata, S., Matsusaka, K., Fukuyo, M., Rahmutulla, B., Mano, Y., Fukayama, M., Aburatani, H., and Kaneda, A. (2016). TET2 functions as a resistance factor against DNA methylation acquisition during Epstein-Barr virus infection. Oncotarget 7, 81512–81526. PMID: 27829228
*Odejide, O., Weigert, O., Lane, A.A., Toscano, D., Lunning, M.A., Kopp, N., Kim, S., Bodegom, D. van, Bolla, S., Schatz, J.H., et al. (2014). A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood 123, 1293–1296. PMID: 24345752
*Pan, F., Weeks, O., Yang, F.-C., and Xu, M. (2015). The TET2 interactors and their links to hematological malignancies. IUBMB Life 67, 438–445. PMID: 26099018
*Patel, J.P., Gönen, M., Figueroa, M.E., Fernandez, H., Sun, Z., Racevskis, J., Van Vlierberghe, P., Dolgalev, I., Thomas, S., Aminova, O., et al. (2012). Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N. Engl. J. Med. 366, 1079–1089. PMID: 22417203
*Patnaik, M.M., Lasho, T.L., Vijayvargiya, P., Finke, C.M., Hanson, C.A., Ketterling, R.P., Gangat, N., and Tefferi, A. (2016). Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia. Blood Cancer J 6, e385. PMID: 26771811
*Quivoron, C., Couronné, L., Della Valle, V., Lopez, C.K., Plo, I., Wagner-Ballon, O., Do Cruzeiro, M., Delhommeau, F., Arnulf, B., Stern, M.-H., et al. (2011). TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 20, 25–38. PMID: 21723201
*Rawłuszko-Wieczorek, A.A., Siera, A., Horbacka, K., Horst, N., Krokowicz, P., and Jagodziński, P.P. (2015). Clinical significance of DNA methylation mRNA levels of TET family members in colorectal cancer. J. Cancer Res. Clin. Oncol. 141, 1379–1392. PMID: 25557833
*Setiawan, V.W., Schumacher, F., Prescott, J., Haessler, J., Malinowski, J., Wentzensen, N., Yang, H., Chanock, S., Brinton, L., Hartge, P., et al. (2014). Cross-cancer pleiotropic analysis of endometrial cancer: PAGE and E2C2 consortia. Carcinogenesis 35, 2068–2073. PMID: 24832084
*Solary, E., Bernard, O.A., Tefferi, A., Fuks, F., and Vainchenker, W. (2014). The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases. Leukemia 28, 485–496. PMID: 24220273
*Steensma, D.P., Bejar, R., Jaiswal, S., Lindsley, R.C., Sekeres, M.A., Hasserjian, R.P., and Ebert, B.L. (2015). Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 126, 9–16. PMID: 25931582
*Swerdlow, S.H., Campo, E., Harris, N.L., Pileri, S.A., Jaffe, E.S., Stein, H., and Thiele, J. (2017). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (International Agency for Research on Cancer).
*Takayama, K., Misawa, A., Suzuki, T., Takagi, K., Hayashizaki, Y., Fujimura, T., Homma, Y., Takahashi, S., Urano, T., and Inoue, S. (2015). TET2 repression by androgen hormone regulates global hydroxymethylation status and prostate cancer progression. Nat Commun 6, 8219. PMID: 26404510
*Tsai, K.-W., Li, G.-C., Chen, C.-H., Yeh, M.-H., Huang, J.-S., Tseng, H.-H., Fu, T.-Y., Liou, H.-H., Pan, H.-W., Huang, S.-F., et al. (2015). Reduction of global 5-hydroxymethylcytosine is a poor prognostic factor in breast cancer patients, especially for an ER/PR-negative subtype. Breast Cancer Res. Treat. 153, 219–234. PMID: 26253945
*Vella, P., Scelfo, A., Jammula, S., Chiacchiera, F., Williams, K., Cuomo, A., Roberto, A., Christensen, J., Bonaldi, T., Helin, K., et al. (2013). Tet Proteins Connect the O-Linked N-acetylglucosamine Transferase Ogt to Chromatin in Embryonic Stem Cells. Molecular Cell 49, 645–656. PMID: 23352454
*Wang, Y., Xiao, M., Chen, X., Chen, L., Xu, Y., Lv, L., Wang, P., Yang, H., Ma, S., Lin, H., et al. (2015). WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation. Mol. Cell 57, 662–673. PMID: 25601757
*Weissmann, S., Alpermann, T., Grossmann, V., Kowarsch, A., Nadarajah, N., Eder, C., Dicker, F., Fasan, A., Haferlach, C., Haferlach, T., et al. (2012). Landscape of TET2 mutations in acute myeloid leukemia. Leukemia 26, 934–942. PMID: 22116554
*Wu, H., and Zhang, Y. (2014). Reversing DNA Methylation: Mechanisms, Genomics, and Biological Functions. Cell 156, 45–68. PMID: 24439369
*Yan, H., Parsons, D.W., Jin, G., McLendon, R., Rasheed, B.A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., and Riggins, G.J. (2009). IDH1 and IDH2 mutations in gliomas. New England Journal of Medicine 360, 765–773. PMID: 23532369
*Yang, L., Yu, S.-J., Hong, Q., Yang, Y., and Shao, Z.-M. (2015). Reduced Expression of TET1, TET2, TET3 and TDG mRNAs Are Associated with Poor Prognosis of Patients with Early Breast Cancer. PLoS ONE 10, e0133896. PMID: 26207381
*Yang, Q., Wu, K., Ji, M., Jin, W., He, N., Shi, B., and Hou, P. (2013). Decreased 5-hydroxymethylcytosine (5-hmC) is an independent poor prognostic factor in gastric cancer patients. J Biomed Nanotechnol 9, 1607–1616. PMID: 23980508
*Zhang, L.-Y., Li, P.-L., Wang, T.-Z., and Zhang, X.-C. (2015). Prognostic values of 5-hmC, 5-mC and TET2 in epithelial ovarian cancer. Arch. Gynecol. Obstet. 292, 891–897. PMID: 25827305
== Notes ==
== Notes ==